Post a Comment Print Share on Facebook

Lilly's Tirzepatide (Mounjaro) emerges as a promising anti-obesity drug

Tirzepatide, an injectable drug developed by Lilly with the trade name Mounjaro, is seen as a promising treatment against obesity after obtaining convincing results that allow patients with type 2 diabetes to lose weight efficiently and sustainably with a weekly injection.

- 36 reads.

Lilly's Tirzepatide (Mounjaro) emerges as a promising anti-obesity drug

Tirzepatide, an injectable drug developed by Lilly with the trade name Mounjaro, is seen as a promising treatment against obesity after obtaining convincing results that allow patients with type 2 diabetes to lose weight efficiently and sustainably with a weekly injection.

A single weekly injection could be as effective for weight loss as bariatric surgery in people with obesity. The drug would benefit patients suffering from insidious type 2 diabetes, in whom losing weight is a therapeutic measure.

Keywords:
EmpresasDirectivosestilovidasaludCiencia Y Salud
Avatar
Your Name
Post a Comment
Characters Left:
Your comment has been forwarded to the administrator for approval.×
Warning! Will constitute a criminal offense, illegal, threatening, offensive, insulting and swearing, derogatory, defamatory, vulgar, pornographic, indecent, personality rights, damaging or similar nature in the nature of all kinds of financial content, legal, criminal and administrative responsibility for the content of the sender member / members are belong.